ATC codes:
L01FA01
EMLc
Indication
Burkitt lymphoma including Burkitt leukaemia
ICD11 code:
2B55.6
INN
Rituximab
Medicine type
Biological agent
List type
Complementary
Additional notes
Including quality-assured biosimilars
Formulations
Parenteral > General injections > IV:
100 mg per 10 mL in 10 mL vial ;
500 mg per 50 mL in 50 mL vial
EML status history
First added in 2023
(TRS
1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Main patents have expired but secondary patents might remain active in some jurisdictions. For more
information on specific patents and license status for developing countries visit www.MedsPal.org
Read more
about patents.
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the current listing for rituximab on the complementary list of the EML and EMLc be extended to include the new indication of Burkitt lymphoma. The Committee noted that rituximab, when added to standard chemotherapy, is associated with meaningful benefits in terms of event-free and overall survival in children and adolescents, with a well-known and acceptable safety profile.